Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome
(AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a
treatment for AWS with encouraging results. Aim of this phase IV, multicenter randomized
double-blind, double dummy study is to evaluate the efficacy of SMO in comparison to oxazepam
in the treatment of alcohol withdrawal symptoms (AWS).
Phase:
Phase 4
Details
Lead Sponsor:
Catholic University of the Sacred Heart
Collaborators:
CT Pharmaceutical Industries, Sanremo - Italy Medical University of Vienna University of Bologna